About biontech se - BNTX
BNTX At a Glance
| Phone | 49-6131-9084-0 | Revenue | 3.24B | |
| Industry | Biotechnology | Net Income | -1,282,177,409.67 | |
| Sector | Health Technology | 2025 Sales Growth | 8.84% | |
| Fiscal Year-end | 12 / 2026 | Employees | 7,807 | |
| View SEC Filings |
BNTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.104 |
| Price to Book Ratio | 1.06 |
| Price to Cash Flow Ratio | 44.71 |
| Enterprise Value to EBITDA | -19.585 |
| Enterprise Value to Sales | 1.82 |
| Total Debt to Enterprise Value | 0.053 |
BNTX Efficiency
| Revenue/Employee | 414,872.02 |
| Income Per Employee | -164,234.329 |
| Receivables Turnover | 2.80 |
| Total Asset Turnover | 0.132 |
BNTX Liquidity
| Current Ratio | 7.537 |
| Quick Ratio | 7.485 |
| Cash Ratio | 6.927 |
BNTX Profitability
| Gross Margin | 77.637 |
| Operating Margin | -22.631 |
| Pretax Margin | -36.615 |
| Net Margin | -39.587 |
| Return on Assets | -5.217 |
| Return on Equity | -6.009 |
| Return on Total Capital | -5.601 |
| Return on Invested Capital | -5.942 |
BNTX Capital Structure
| Total Debt to Total Equity | 1.391 |
| Total Debt to Total Capital | 1.372 |
| Total Debt to Total Assets | 1.216 |
| Long-Term Debt to Equity | 1.119 |
| Long-Term Debt to Total Capital | 1.104 |
Biontech Se in the News
Pfizer shares sink after it resets 2024 COVID expectations
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low.
Vaccine makers see stock price boost on Biden admin COVID shot push
News that the Biden administration is planning to push for Americans to get the updated COVID vaccines this fall caused several vaccine manufacturers' stock prices to rise Monday.
China approves Livzon Pharmaceutical's COVID vaccine as a booster
With COVID cases on the rise in China, the government has approved Livzon Pharmaceutical's COVID-19 vaccine as a booster, in hopes of having as many people boosted as possible.
Pfizer and BioNTech COVID vaccine 73.2% effective in children under 5, according to new data
Pfizer Inc and BioNTech's COVID vaccine was approved for use in children under 5 years old in June, and new studies have shown the vaccine to be 73.2% effective within that age group.
Pfizer looks for US approval on updated COVID booster that targets omicron variant
Pfizer Inc and BioNTech announced on Monday that they are looking for the U.S. to approve their retooled COVID booster, which targets the omicron variant.
Curevac sues BioNTech over COVID-19 vaccine's mRNA technology
CureVac is suing Pfizer's German partner BioNTech for alleged patent infringement related to the development of their mRNA vaccines against COVID-19.
FDA authorizes Pfizer booster shots for kids ages 5-11
The U.S. Food and Drug Administration (FDA) amended the emergency use authorization for Pfizer-BioNTech COVID-19 vaccine. The agency is allowing the use of a single booster dose in kids ages 5 to 11.
Pfizer COVID-19 vaccine less effective in ages 5-11: study
Two doses of the Pfizer Inc. and BioNTech SE COVID-19 vaccine was protective against severe disease in children aged 5 to 11 during the recent omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers.
Pfizer submits request for COVID-19 vaccine use in children under age 5
Pfizer and BioNTech said Tuesday that the companies had asked the Food and Drug Administration (FDA) to authorize their COVID-19 vaccine for emergency use in children younger than 5 years old.
Pfizer, BioNTech begin omicron-specific COVID-19 vaccine study
COVID-19 vaccine-makers Pfizer and BioNTech announced Tuesday that the companies would test an omicron-specific vaccine candidate in healthy adults ages 18 to 55.